Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1

Giulio Francolini; Mette S Thomsen; Esben S Yates; Carine Kirkove; Ingelise Jensen; Egil S Blix; Claus Kamby; Mette H Nielsen; Mechthild Krause; Martin Berg; Ingvil Mjaaland; Andreas Schreiber; Unn-Miriam Kasti; Kristian Boye; Birgitte V Offersen

doi:10.1016/j.radonc.2017.03.011

Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1

Giulio Francolini, Mette S Thomsen, Esben S Yates, Carine Kirkove, Ingelise Jensen, Egil S Blix, Claus Kamby, Mette H Nielsen, Mechthild Krause, Martin Berg, Ingvil Mjaaland, Andreas Schreiber, Unn-Miriam Kasti, Kristian Boye, Birgitte V Offersen

Research output: Contribution to journal › Journal article › Research › peer-review

17 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE: To report on a Quality assessment (QA) of Skagen Trial 1, exploring hypofractionation for breast cancer patients with indication for regional nodal radiotherapy.

MATERIAL AND METHODS: Deviations from protocol regarding target volume delineations and dose parameters (Dmin, Dmax, D98%, D95% and D2%) from randomly selected dose plans were assessed. Target volume delineation according to ESTRO guidelines was obtained through atlas based automated segmentation and centrally approved as gold standard (GS). Dice similarity scores (DSC) with original delineations were measured. Dose parameters measured in the two delineations were reported to assess their dosimetric outcome.

RESULTS: Assessment included 88 plans from 12 centres in 4 countries. DSC showed high agreement in contouring, 99% and 96% of the patients had a complete delineation of target volumes and organs at risk. No deviations in the dosimetric outcome were found in 76% of the patients, 82% and 95% of the patients had successful coverage of breast/chestwall and CTVn_L2-4-interpectoral. Dosimetric outcomes of original delineation and GS were comparable.

CONCLUSIONS: QA showed high protocol compliance and adequate dose coverage in most patients. Inter-observer variability in contouring was low. Dose parameters were in harmony with protocol regardless original or GS segmentation.

Original language	English
Journal	Radiotherapy & Oncology
Volume	123
Issue number	2
Pages (from-to)	282-287
Number of pages	6
ISSN	0167-8140
DOIs	https://doi.org/10.1016/j.radonc.2017.03.011
Publication status	Published - 2017

Keywords

Journal Article

Access to Document

10.1016/j.radonc.2017.03.011

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Francolini, G., Thomsen, M. S., Yates, E. S., Kirkove, C., Jensen, I., Blix, E. S., Kamby, C., Nielsen, M. H., Krause, M., Berg, M., Mjaaland, I., Schreiber, A., Kasti, U.-M., Boye, K., & Offersen, B. V. (2017). Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1. Radiotherapy & Oncology, 123(2), 282-287. https://doi.org/10.1016/j.radonc.2017.03.011

@article{d015e6d31c32462fb94379b71b1138e0,

title = "Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1",

abstract = "BACKGROUND AND PURPOSE: To report on a Quality assessment (QA) of Skagen Trial 1, exploring hypofractionation for breast cancer patients with indication for regional nodal radiotherapy.MATERIAL AND METHODS: Deviations from protocol regarding target volume delineations and dose parameters (Dmin, Dmax, D98%, D95% and D2%) from randomly selected dose plans were assessed. Target volume delineation according to ESTRO guidelines was obtained through atlas based automated segmentation and centrally approved as gold standard (GS). Dice similarity scores (DSC) with original delineations were measured. Dose parameters measured in the two delineations were reported to assess their dosimetric outcome.RESULTS: Assessment included 88 plans from 12 centres in 4 countries. DSC showed high agreement in contouring, 99% and 96% of the patients had a complete delineation of target volumes and organs at risk. No deviations in the dosimetric outcome were found in 76% of the patients, 82% and 95% of the patients had successful coverage of breast/chestwall and CTVn_L2-4-interpectoral. Dosimetric outcomes of original delineation and GS were comparable.CONCLUSIONS: QA showed high protocol compliance and adequate dose coverage in most patients. Inter-observer variability in contouring was low. Dose parameters were in harmony with protocol regardless original or GS segmentation.",

keywords = "Journal Article",

author = "Giulio Francolini and Thomsen, {Mette S} and Yates, {Esben S} and Carine Kirkove and Ingelise Jensen and Blix, {Egil S} and Claus Kamby and Nielsen, {Mette H} and Mechthild Krause and Martin Berg and Ingvil Mjaaland and Andreas Schreiber and Unn-Miriam Kasti and Kristian Boye and Offersen, {Birgitte V}",

year = "2017",

doi = "10.1016/j.radonc.2017.03.011",

language = "English",

volume = "123",

pages = "282--287",

journal = "Radiotherapy & Oncology",

issn = "0167-8140",

publisher = "Elsevier",

number = "2",

}

Francolini, G, Thomsen, MS, Yates, ES, Kirkove, C, Jensen, I, Blix, ES, Kamby, C, Nielsen, MH, Krause, M, Berg, M, Mjaaland, I, Schreiber, A, Kasti, U-M, Boye, K & Offersen, BV 2017, 'Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1', Radiotherapy & Oncology, vol. 123, no. 2, pp. 282-287. https://doi.org/10.1016/j.radonc.2017.03.011

TY - JOUR

T1 - Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1

AU - Francolini, Giulio

AU - Thomsen, Mette S

AU - Yates, Esben S

AU - Kirkove, Carine

AU - Jensen, Ingelise

AU - Blix, Egil S

AU - Kamby, Claus

AU - Nielsen, Mette H

AU - Krause, Mechthild

AU - Berg, Martin

AU - Mjaaland, Ingvil

AU - Schreiber, Andreas

AU - Kasti, Unn-Miriam

AU - Boye, Kristian

AU - Offersen, Birgitte V

PY - 2017

Y1 - 2017

N2 - BACKGROUND AND PURPOSE: To report on a Quality assessment (QA) of Skagen Trial 1, exploring hypofractionation for breast cancer patients with indication for regional nodal radiotherapy.MATERIAL AND METHODS: Deviations from protocol regarding target volume delineations and dose parameters (Dmin, Dmax, D98%, D95% and D2%) from randomly selected dose plans were assessed. Target volume delineation according to ESTRO guidelines was obtained through atlas based automated segmentation and centrally approved as gold standard (GS). Dice similarity scores (DSC) with original delineations were measured. Dose parameters measured in the two delineations were reported to assess their dosimetric outcome.RESULTS: Assessment included 88 plans from 12 centres in 4 countries. DSC showed high agreement in contouring, 99% and 96% of the patients had a complete delineation of target volumes and organs at risk. No deviations in the dosimetric outcome were found in 76% of the patients, 82% and 95% of the patients had successful coverage of breast/chestwall and CTVn_L2-4-interpectoral. Dosimetric outcomes of original delineation and GS were comparable.CONCLUSIONS: QA showed high protocol compliance and adequate dose coverage in most patients. Inter-observer variability in contouring was low. Dose parameters were in harmony with protocol regardless original or GS segmentation.

AB - BACKGROUND AND PURPOSE: To report on a Quality assessment (QA) of Skagen Trial 1, exploring hypofractionation for breast cancer patients with indication for regional nodal radiotherapy.MATERIAL AND METHODS: Deviations from protocol regarding target volume delineations and dose parameters (Dmin, Dmax, D98%, D95% and D2%) from randomly selected dose plans were assessed. Target volume delineation according to ESTRO guidelines was obtained through atlas based automated segmentation and centrally approved as gold standard (GS). Dice similarity scores (DSC) with original delineations were measured. Dose parameters measured in the two delineations were reported to assess their dosimetric outcome.RESULTS: Assessment included 88 plans from 12 centres in 4 countries. DSC showed high agreement in contouring, 99% and 96% of the patients had a complete delineation of target volumes and organs at risk. No deviations in the dosimetric outcome were found in 76% of the patients, 82% and 95% of the patients had successful coverage of breast/chestwall and CTVn_L2-4-interpectoral. Dosimetric outcomes of original delineation and GS were comparable.CONCLUSIONS: QA showed high protocol compliance and adequate dose coverage in most patients. Inter-observer variability in contouring was low. Dose parameters were in harmony with protocol regardless original or GS segmentation.

KW - Journal Article

U2 - 10.1016/j.radonc.2017.03.011

DO - 10.1016/j.radonc.2017.03.011

M3 - Journal article

C2 - 28351523

SN - 0167-8140

VL - 123

SP - 282

EP - 287

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

IS - 2

ER -

Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1

Abstract

Keywords

Access to Document

AUB Link

Fingerprint

Cite this